NINTEDANIB ESYLATE | BOEHRINGER INGELHEIM | ||
EQ 100MG BASE,EQ 150MG BASE | |||
Yes | No | ||
2029-Dec-07 | 2019-Oct-15 | ||
2021-Oct-15 | None | ||
None | No | ||
OFEV is a kinase inhibitor indicated in adults for: • Treatment of idiopathic pulmonary fibrosis (IPF). • Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype • Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). |
0 | 4 | 0 |
Total Other Developers | 14 |
---|
Drugs with Suitability | No |
---|
EQ 100MG BASE | ** | ** | - | - | - |
EQ 150MG BASE | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com